Edwards Lifesciences Corp. has beaten its rivals to yet another milestone in the development of transcatheter aortic valve replacement (TAVR) systems with the first US FDA-approved indication for intermediate-risk patients.
US FDA Approves First Intermediate-Risk Indication For TAVR
The expanded indication for Edwards' Sapien XT and Sapien 3 arrives about when the company had predicted.